Clinical Trial Detail

NCT ID NCT02658279
Title Pembrolizumab (MK-3475) in Patients With Recurrent Malignant Glioma With a Hypermutator Phenotype
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors Memorial Sloan Kettering Cancer Center
Indications

malignant glioma

Therapies

Pembrolizumab

Age Groups: adult senior

Additional content available in CKB BOOST